Skip to main content
SpringerLink
Log in

Isolated Limb Perfusion for Extremity Soft Tissue Sarcoma and Malignant Melanoma

  • Review Article
  • Published:
Indian Journal of Surgical Oncology Aims and scope Submit manuscript

Abstract

Isolated limb perfusion (ILP) is a regional chemotherapy technique used in the treatment of locally advanced or unresectable extremity soft tissue sarcoma (ESTS) or malignant melanoma (MM) of the limbs. It allows for high concentrations of chemotherapeutic agents to be perfused in the limb while minimising the risk of systemic side-effects. While the technique has been utilized for decades, the role of ILP has evolved as other treatment strategies have become available. Current indications for ILP in sarcoma include induction in unresectable ESTS to allow for future definitive limb preservation procedures as well as definitive treatment of unresectable, multifocal ESTS. In MM, ILP is typically used in unresectable in-transit melanoma, and rarely as an alternative to amputation in bulky, symptomatic extremity disease. This review seeks to summarise the current evidence base and indications for ILP as well as present some technical insights from a high-volume United Kingdom (UK) unit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data Availability

Data is available by request to corresponding author.

References

  1. Jakob J et al (2018) Regional chemotherapy by isolated limb perfusion prior to surgery compared with surgery and post-operative radiotherapy for primary, locally advanced extremity sarcoma: a comparison of matched cohorts. Clin Sarcoma Res 8:1–9

    Article  Google Scholar 

  2. Sevilla-Ortega L et al (2021) Role of isolated limb perfusion in the era of targeted therapies and immunotherapy in melanoma. A systematic review of the literature. Cancers (Basel) 13:5485

  3. Bhangu A, Broom L, Nepogodiev D, Gourevitch D, Desai A (2013) Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: A systematic review. Eur J Surg Oncol 39:311–319

    Article  CAS  PubMed  Google Scholar 

  4. Davies EJ, Reijers SJM, Van Akkooi ACJ, Van Houdt WJ, Hayes AJ (2022) Isolated limb perfusion for locally advanced melanoma in the immunotherapy era. Eur J Surg Oncol 48:1288–1292

    Article  CAS  PubMed  Google Scholar 

  5. Klopp CT, Alford TC, Bateman J, Berry GN, Winship T (1950) Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. Ann Surg 132:811–832

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Creech O Jr, Ryan RF, Krementz ET (1959) Treatment of melanoma by isolation-perfusion technique. J Am Med Assoc 169:339–343

    Article  PubMed  Google Scholar 

  7. Cavaliere R et al (1967) Selective heat sensitivity of cancer cells. Biochem Clin Stud Cancer 20:1351–1381

    CAS  Google Scholar 

  8. Grünhagen DJ, de Wilt JHW, ten Hagen TLM, Eggermont AMM (2006) Technology Insight: utility of TNF-α-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 3:94–103

    Article  PubMed  Google Scholar 

  9. Moreno-Ramirez D, Cruz-Merino L, Ferrandiz L, Villegas-Portero R, Nieto-Garcia A (2010) Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and Safety. Oncologist 15:416–427

    Article  PubMed  PubMed Central  Google Scholar 

  10. Vrouenraets BC, Nieweg OE, Kroon BBR (1996) Thirty-five years of isolated limb perfusion for melanoma: Indications and results. Br J Surg 83:1319–1328

    Article  CAS  PubMed  Google Scholar 

  11. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol Off J Am Soc Clin Oncol 10:52–60

    Article  CAS  Google Scholar 

  12. Lejeune FJ (2002) Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 110:433–435

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Van Der Veen AH et al (2000) TNF-α augments intratumoural concentrations of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 82:973–980

    Article  PubMed  PubMed Central  Google Scholar 

  14. Eggermont AMM et al (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: The cumulative multicenter European experience. Ann Surg 224:756–765

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bonvalot S et al (2009) Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol 16:3350–3357

    Article  PubMed  Google Scholar 

  16. Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM (2007) Isolated limb perfusion with melphalan and tumor necrosis factor α for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol 14:230–238

    Article  PubMed  Google Scholar 

  17. Bonvalot S et al (2005) Limb salvage with isolated perfusion for soft tissue sarcoma: Could less TNF-α be better? Ann Oncol 16:1061–1068

    Article  CAS  PubMed  Google Scholar 

  18. Podleska LE et al (2014) Drug dosage in isolated limb perfusion: Evaluation of a limb volume model for extremity volume calculation. World J Surg Oncol 12:1–9

    Article  Google Scholar 

  19. Deroose JP et al (2011) Long-term results of tumor necrosis factor α- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 29:4036–4044

    Article  CAS  PubMed  Google Scholar 

  20. Van Ginkel RJ et al (2007) Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: Three time periods at risk for amputation. Ann Surg Oncol 14:1499–1506

    Article  PubMed  PubMed Central  Google Scholar 

  21. Erdmann F et al (2013) International trends in the incidence of malignant melanoma 1953–2008-are recent generations at higher or lower risk? Int J Cancer 132:385–400

    Article  CAS  PubMed  Google Scholar 

  22. Gershenwald JE, Scolyer RA (2018) Melanoma staging: American joint committee on cancer (AJCC) 8th edition and beyond. Ann Surg Oncol 25:2105–2110

    Article  PubMed  Google Scholar 

  23. Wolchok JD et al (2022) Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 40:127–137

    Article  CAS  PubMed  Google Scholar 

  24. Lebbé C et al (2019) Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: Results from the phase IIIb/IV CheckMate 511 trial. J Clin Oncol 37:867–875

    Article  PubMed  PubMed Central  Google Scholar 

  25. Ascierto PA et al (2013) Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 31:3205–3211

    Article  CAS  PubMed  Google Scholar 

  26. Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S (2018) Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2018

  27. Hayes AJ, Clark MA, Harries M, Thomas JM (2004) Management of in-transit metastases from cutaneous malignant melanoma. Br J Surg 91:673–682

    Article  CAS  PubMed  Google Scholar 

  28. Read RL et al (2015) In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. Ann Surg Oncol 22:475–481

    Article  PubMed  Google Scholar 

  29. Andtbacka RHI et al (2019) Final analyses of OPTiM: A randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer 7:1–11

    Article  Google Scholar 

  30. Nan Tie E, Henderson MA, Gyorki DE (2019) Management of in-transit melanoma metastases: a review. ANZ J Surg 89:647–652

    Article  PubMed  Google Scholar 

  31. Patel A, Carr MJ, Sun J, Zager JS (2022) In-transit metastatic cutaneous melanoma: current management and future directions. Clin Exp Metastasis 39:201–211

    Article  PubMed  Google Scholar 

  32. Eggermont AMM et al (2016) Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 375:1845–1855

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Schachter J et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390:1853–1862

    Article  CAS  PubMed  Google Scholar 

  34. Weber J et al (2017) Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 377:1824–1835

    Article  CAS  PubMed  Google Scholar 

  35. Long GV et al (2017) Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma. N Engl J Med 377:1813–1823

    Article  CAS  PubMed  Google Scholar 

  36. Deroose JP et al (2012) 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann Surg Oncol 19:627–635

    Article  PubMed  Google Scholar 

  37. Koops HS et al (1998) Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World He. J Clin Oncol Off J Am Soc Clin Oncol 16:2906–2912

    Article  CAS  Google Scholar 

  38. Cornett WR et al (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group trial Z0020. J Clin Oncol 24:4196–4201

    Article  CAS  PubMed  Google Scholar 

  39. Lejeune FJ, Eggermont AMM (2007) Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs [7]. J Clin Oncol 25:1449–1450

    Article  PubMed  Google Scholar 

  40. Thompson JF, Kam PC, Waugh RC, Harman CR (1998) Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 14:238–247

    Article  CAS  PubMed  Google Scholar 

  41. Beasley GM et al (2008) Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 15:2195–2205

    Article  PubMed  Google Scholar 

  42. Dossett LA, Ben-Shabat I, OlofssonBagge R, Zager JS (2016) Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma. Ann Surg Oncol 23:2330–2335

    Article  PubMed  Google Scholar 

  43. Dangoor A et al (2016) UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res 6:1–26

    Article  Google Scholar 

  44. Grimer R, Judson I, Peake D, Seddon B (2010) Guidelines for the management of soft tissue sarcomas. Sarcoma 2010

  45. Coindre JM et al (2001) Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91:1914–1926

    Article  CAS  PubMed  Google Scholar 

  46. Wray CJ et al (2011) Isolated limb perfusion for unresectable extremity sarcoma. Cancer 117:3235–3241

    Article  PubMed  Google Scholar 

  47. Kaushal A, Citrin D (2008) The Role of Radiation Therapy in the Management of Sarcomas. Surg Clin North Am 88:629–646

    Article  PubMed  PubMed Central  Google Scholar 

  48. Woll PJ et al (2012) Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): A multicentre randomised controlled trial. Lancet Oncol 13:1045–1054

    Article  CAS  PubMed  Google Scholar 

  49. Gronchi A et al (2017) Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18:812–822

    Article  CAS  PubMed  Google Scholar 

  50. Pasquali S et al (2022) Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. Cancer 128:85–93

    Article  CAS  PubMed  Google Scholar 

  51. Squires MH et al (2022) Extremity soft tissue sarcoma: a multi-institutional validation of prognostic nomograms. Ann Surg Oncol 29:3291–3301

    Article  PubMed  Google Scholar 

  52. O’Donnell PW et al (2014) The effect of the setting of a positive surgical margin in soft tissue sarcoma. Cancer 120:2866–2875

    Article  PubMed  Google Scholar 

  53. O’Sullivan B et al (2002) Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet (London, England) 359:2235–2241

    Article  PubMed  Google Scholar 

  54. Davis AM et al (2005) Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol J Eur Soc Ther Radiol Oncol 75:48–53

    Article  Google Scholar 

  55. Chung PWM et al (2009) Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: A comparison with other soft tissue sarcomas. Cancer 115:3254–3261

    Article  PubMed  Google Scholar 

  56. Hoekstra HJ, SchraffordtKoops H, Molenaar WM, Oldhoff J (1987) Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer 60:1703–1707

    Article  CAS  PubMed  Google Scholar 

  57. Stehlin JSJ, de Ipolyi PD, Giovanella BC, Gutierrez AE, Anderson RF (1975) Soft tissue sarcomas of the extremity. Multidisciplinary therapy employing hyperthermic perfusion. Am J Surg 130:643–646

    Article  PubMed  Google Scholar 

  58. Grunhagen DJ et al (2006) Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-α and melphalan for limb-threatening soft tissue sarcoma. Cancer 106:1776–1784

    Article  CAS  PubMed  Google Scholar 

  59. Gutman M et al (1997) High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 79:1129–1137

    Article  CAS  PubMed  Google Scholar 

  60. Lejeune FJ et al (2000) Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 26:669–678

    CAS  Google Scholar 

  61. Noorda EM et al (2003) Isolated limb perfusion with tumor necrosis factor-α and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer 98:1483–1490

    Article  CAS  PubMed  Google Scholar 

  62. Neuwirth MG et al (2017) Isolated limb perfusion and infusion for extremity soft tissue sarcoma: a contemporary systematic review and meta-analysis. Ann Surg Oncol 24:3803–3810

    Article  PubMed  Google Scholar 

  63. Lans TE, Grünhagen DJ, De Wilt JHW, Van Geel AN, Eggermont AMM (2005) Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol 12:406–411

    Article  CAS  PubMed  Google Scholar 

  64. In’t Veld EH et al (2017) Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study. Eur J Cancer 85:114–121

    Article  Google Scholar 

  65. Hoven-Gondrie ML et al (2008) Isolated limb perfusion and external beam radiotherapy for soft tissue sarcomas of the extremity: Long-term effects on normal tissue according to the LENT-SOMA scoring system. Ann Surg Oncol 15:1502–1510

    Article  PubMed  PubMed Central  Google Scholar 

  66. Pennacchioli E et al (2007) Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol 14:553–559

    Article  PubMed  Google Scholar 

  67. Rastrelli M et al (2016) Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience. Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Gr 32:165–172

    Article  Google Scholar 

  68. Hill S et al (1993) Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 80:995–997

    Article  CAS  PubMed  Google Scholar 

  69. Vaglini M et al (1994) Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 73:483–492

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sarcoma and Melanoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London, UK

    Michael Russell, Michelle Wilkinson & Andrew Hayes

  2. Institute of Cancer Research, 237 Fulham Road, London, SW3 6JJ, UK

    Andrew Hayes

Authors
  1. Michael Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle Wilkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew Hayes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Russell.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Russell, M., Wilkinson, M. & Hayes, A. Isolated Limb Perfusion for Extremity Soft Tissue Sarcoma and Malignant Melanoma. Indian J Surg Oncol (2024). https://doi.org/10.1007/s13193-024-01920-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13193-024-01920-2

Keywords

Search

Navigation